An open single center single arm clinical study for anti-BCMA CAR-T therapy for relapsed, refractory and high-risk BCMA+ tumor
Latest Information Update: 21 Jun 2019
At a glance
- Drugs Anti-BCMA-chimeric-antigen-receptor-T-cell-therapy-Wuhan-Bio-Raid-Biotechnology (Primary)
- Indications Leukaemia; Lymphoma; Multiple myeloma
- Focus Adverse reactions
- 21 Jun 2019 Planned number of patients changed from 50 to 100.
- 15 Sep 2016 New trial record